financetom
Business
financetom
/
Business
/
--Costamare Maintains Quarterly Dividend at $0.115 Per Common Share, Payable May 6 to Shareholders of Record April 17
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
--Costamare Maintains Quarterly Dividend at $0.115 Per Common Share, Payable May 6 to Shareholders of Record April 17
Apr 2, 2025 8:16 AM

10:43 AM EDT, 04/02/2025 (MT Newswires) --

Price: 10.21, Change: -0.06, Percent Change: -0.58

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Merck's oral HIV treatment non-inferior to Gilead's Biktarvy in late-stage trial 
Merck's oral HIV treatment non-inferior to Gilead's Biktarvy in late-stage trial 
Nov 19, 2025
Nov 19 (Reuters) - Merck ( MRK ) said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy in a late-stage study in adults with HIV who had not previously received treatment. The Rahway, New Jersey-based company was testing its oral, two-drug regimen of doravirine and islatravir in adults with HIV-1 infection...
Target Hit By Traffic, Profit Decline Heading Into Holiday Season
Target Hit By Traffic, Profit Decline Heading Into Holiday Season
Nov 19, 2025
Target Corporation ( TGT ) stock slipped in early trading on Thursday as the retailer reported a third-quarter profit beat but posted underwhelming sales and trimmed its full-year earnings outlook heading into the crucial holiday stretch. At the same time, the big-box chain is leaning into an attention-grabbing artificial intelligence push, wiring its aisles into ChatGPT through an expanded OpenAI...
Regeneron Pharmaceuticals Gets European Commission's Approval for Expanded Indication for Libtayo
Regeneron Pharmaceuticals Gets European Commission's Approval for Expanded Indication for Libtayo
Nov 19, 2025
08:32 AM EST, 11/19/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said Wednesday it has received the European Commission's approval for its PD-1 inhibitor Libtayo as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma. The approval expands the existing EU indication for Libtayo to include patients at high risk of disease recurrence after surgery and radiation,...
Troilus Gold Upsizes Debt Financing Mandate to US$1 Billion
Troilus Gold Upsizes Debt Financing Mandate to US$1 Billion
Nov 19, 2025
08:33 AM EST, 11/19/2025 (MT Newswires) -- Troilus Gold ( CHXMF ) on Wednesday increased its previously announced debt financing mandate to up to US$1 billion from $700 million. The company said the financing will support the development and construction of the copper-gold Troilus project, located in north-central Quebec, Canada. Auramet International is acting as project finance advisor. It said...
Copyright 2023-2026 - www.financetom.com All Rights Reserved